Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy

Bibliography

• Mocellin S. New strategies to improve the efficacy of colorectal cancer vaccines: from bench to bedside. Curr Opin Investig Drugs 2006;7(12):1052-61
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12(10):3064-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15
   PubMed Web of Science ®Google Scholar
• Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Cancer vaccines: pessimism in check. Nat Med 2004;10(12):1278-9; author reply 1279-80
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Levy R. Cancer vaccines: pessimism in check. Nat Med 2004;10(12):1279; author reply 1279-80
   PubMedGoogle Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305(5681):200-5
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-48
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95(13):7556-61
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410(6832):1107-11
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6(10):715-27
   PubMed Web of Science ®Google Scholar
• Elkord E. Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Dis 2007;10(3):224-36
   PubMed Web of Science ®Google Scholar
• Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 2002;3(11):999-1005
   PubMed Web of Science ®Google Scholar
• Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22(6):1136-51
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3(8):342-9
   PubMedGoogle Scholar
• Smyth LJ, Elkord E, Taher TE, et al. CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer 2006;119(7):1638-47
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54(3):187-207
   PubMed Web of Science ®Google Scholar
• Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines 2005;4(3):329-50
   PubMed Web of Science ®Google Scholar
• Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997;3(8):1267-76
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84(14):1084-91
   PubMed Web of Science ®Google Scholar
• Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5(6):1331-8
   PubMed Web of Science ®Google Scholar
• Ludewig B, Ochsenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191(5):795-804
   PubMed Web of Science ®Google Scholar
• Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997;20(4):416-8
   PubMed Web of Science ®Google Scholar
• King M, Spooner D, Rowlands DC. Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: a case report and a review of the literature. Clin Oncol (R Coll Radiol) 2001;13(6):466-9
   PubMed Web of Science ®Google Scholar
• Di Giorgio A, Botti C, Tocchi A, et al. The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg 1992;77(4):256-60
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79(12):2320-8
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58(16):3491-4
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4
   PubMed Web of Science ®Google Scholar
• Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55(9):1064-71
   PubMed Web of Science ®Google Scholar
• Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98(5):1089-99
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9(12):4296-303
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, Van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353(9150):345-50
   PubMed Web of Science ®Google Scholar
• Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18(1):148-57
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006;12(7 Pt 2):s2337-41
   PubMed Web of Science ®Google Scholar
• Thompson PL, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol 2007;601:345-55
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005;23(5):999-1010
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fukuhara T, Tanaka M, et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005;11(1):58-66
   PubMed Web of Science ®Google Scholar
• Yasuda T, Kamigaki T, Kawasaki K, et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 2007;56(7):1025-36
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin Cancer Res 2006;12(11 Pt 1):3416-24
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13(15 Pt 1):4487-94
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23(4):720-31
   PubMed Web of Science ®Google Scholar
• Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Ann Rev Immunol 2007;25:243-65
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202(7):907-12
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy – how far can we go? Nat Clin Pract Oncol 2006;3(12):668-81
   PubMedGoogle Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23(10):2346-57
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006;177(9):6527-39
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126-9
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86(24):10024-8
   PubMed Web of Science ®Google Scholar
• Movassagh M, Boyer O, Burland MC, et al. Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum Gene Ther 2000;11(8):1189-200
   PubMed Web of Science ®Google Scholar
• Thistlethwaite F, Mansoor W, Gilham DE, Hawkins RE. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther 2005;7(1):48-55
   PubMed Web of Science ®Google Scholar
• Forsberg G, Ohlsson L, Brodin T, et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 2001;85(1):129-36
   PubMed Web of Science ®Google Scholar
• Shaw DM, Connolly NB, Patel PM, et al. A Phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer 2007;96(4):567-74
   PubMed Web of Science ®Google Scholar
• Arnold D, Siewczynski R, Schmoll HJ. The integration of targeted agents into systemic therapy of metastatic colorectal cancer. Ann Oncol 2006;17 Suppl 10:x122-8
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007;26(25):3661-78
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19(56):6550-65
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23-30
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz HJ, Kindler HL, et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25(29):4557-61
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19(1):92-8
   PubMedGoogle Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117(5):1167-74
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34(2):336-44
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106(6):2018-25
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623-33
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120(12):2723-33
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007;179(7):4919-28
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27
   PubMed Web of Science ®Google Scholar
• Thistlethwaite FC, Elkord E, Griffiths RW, et al. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2007
   Google Scholar
• Powell DJ Jr, De Vries CR, Allen T, et al. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 2007;30(4):438-47
   PubMed Web of Science ®Google Scholar
• Nair S, Boczkowski D, Fassnacht M, et al. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007;67(1):371-80
   PubMed Web of Science ®Google Scholar
• Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7(11):880-7
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10(1):15-8
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117(5):1147-54
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64(16):5839-49
   PubMed Web of Science ®Google Scholar
• Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65(8):3044-8
   PubMed Web of Science ®Google Scholar
• Brown JR, Dubois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23(12):2840-55
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107(4):1183-8
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202(7):931-9
   PubMed Web of Science ®Google Scholar
• Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a Phase II study. Int J Cancer 2003;105(6):868-72
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Murillo O, Atorrasagasti C, et al. Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007;13(44):5822-31
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7(2):95-106
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen JH, Fu Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol 2004;1(1):31-6
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100(14):8372-7
   PubMed Web of Science ®Google Scholar
• Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006;24(5):442-7
   PubMed Web of Science ®Google Scholar
• Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Ann Rev Immunol 2006;24:65-97
   PubMed Web of Science ®Google Scholar
• Kocak E, Lute K, Chang X, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006;66(14):7276-84
   PubMed Web of Science ®Google Scholar
• Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65(3):1089-96
   PubMed Web of Science ®Google Scholar
• Arlen PM, Madan RA, Hodge JW, et al. Combining vaccines with conventional therapies for cancer. Update Cancer Ther 2007;2(1):33-9
   PubMedGoogle Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13(13):3776-82
   PubMed Web of Science ®Google Scholar
• Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65(18):8059-64
   PubMed Web of Science ®Google Scholar
• North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;155(4):1063-74
   PubMed Web of Science ®Google Scholar
• Correale P, Del Vecchio MT, Di Genova G, et al. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 2005;97(19):1437-45
   PubMed Web of Science ®Google Scholar
• Jiang HR, Gilham DE, Mulryan K, et al. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol 2006;177(7):4288-98
   PubMed Web of Science ®Google Scholar
• Gulley JL, Dahut WL. Future directions in tumor immunotherapy: CTLA4 blockade. Nat Clin Pract Oncol 2007;4(3):136-7
   PubMedGoogle Scholar
• Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116(7):1935-45
   PubMed Web of Science ®Google Scholar
• Tuve S, Chen BM, Liu Y, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67(12):5929-39
   PubMed Web of Science ®Google Scholar
• Cuadros C, Dominguez AL, Lollini PL, et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005;116(6):934-43
   PubMed Web of Science ®Google Scholar